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INTRODUCTION
Charcot foot is a relatively uncommon complication ofdiabetes but one which can lead to chronic ulceration,
marked deformity and amputation.  Although its aetiology
is not fully understood, several advances have occurred in
its management.  Surgery has a definite role to play but the
mainstay of initial treatment is non-operative.  Correct
diagnosis can prevent progressive deformity.  The timing
and type of surgery are crucially important as inappropriate
surgery may worsen the problem and lead to premature
amputation.
INCIDENCE
Charcot foot or neuroarthropathy, is estimated to affect
between 1-2.5% of people with diabetes.1  It is most common
in people with Type 1 diabetes in the fifth and sixth decade
of life but can occur in young patients and in Type 2 diabetic
patients as well.  Usually, the duration of diabetes is greater
than 12 years.2  In most cases, it is unilateral but it may be
bilateral in upto 25% of patients.3
In a study of about 20,000 consecutive diabetic patients,
Bailey and Root4 reported 17 cases of Charcot’s disease
(prevalence 1:1100).  However, many cases may have
escaped recognition since the criterion for diagnosis was the
presence of unilateral or bilateral thickening in the mid-foot.
This is a late sign, indicative of significant joint destruction
and bony fragmentation and adaptation.  The most
comprehensive study to date, conducted by Sinha5 found 101
cases of Charcot’s disease among 68,000 consecutive diabetic
patients (prevalence 1:680).
DEFINITION
Charcot foot can be defined as a relatively painless,
progressive and degenerative arthropathy of single or
multiple joints caused by an underlying neurological deficit.
The amount of destruction and deformity seen clinically and
on X ray can be quite considerable.
CAUSES
The association between a neurological deficit and an
arthropathy was first suggested by Mitchell, an American
physician, although it was Jean-Marie Charcot who famously
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attached his name to this condition.6  Charcot observed the
association between tabes dorsalis (due to syphilis) and
arthropathy and even without the use of X rays, described
the natural history of the condition.  Although diabetes is
today is the main cause of Charcot joints in the developed
world, other neuropathies can cause Charcot joints and in
some countries leprosy may be the commonest cause. The
causes of Charcot foot are summarized in Table 1.
Table 1.  Reported causes of charcot foot
1. Diabetes (major cause)
2. Leprosy (Hansen’s disease)
3. Tabes dorsalis
4. Spinal cord tumor
5. Charcot Marie Tooth disease
6. Pernicious anaemia
7. Medications like steroids, phenylbutazone,
indomethacin, vincristine
8. Alcoholism
9. Cerebral palsy
10. Hereditary insensitivity to pain
11. Myelodysplasia
12. Poliomyelitis
13. Syringomyelia
14. Tertiary syphilis
ETIOLOGY
Two popular theories had been proposed to describe the
cause of Charcot’s disease.
I.  French Theory
II. German Theory
The French theory6 espoused by Charcot postulated that
a spinal cord lesion occurred that allowed trophic changes
in the joints.  This theory was based on the observation that
changes in the joints were always preceded by sclerotic
changes in the spinal cord.
The German theory described by Volkman and Virchow7
proposed that it was due to microtrauma, i.e., repeated
unperceived subclinical trauma to insensitive joints.  Loss
of protective sensation allows abnormal mechanical stresses
which would normally be prevented due to pain.  This may
then lead on to spontaneous fractures, subluxations and
dislocations.
A vascular theory has recently been proposed.8-11
Charcot’s disease occurs most commonly in patients with
palpable (often strongly so), pedal pulses.  Also, several cases
following lower extremity re-vascularization have been
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described.11 The presence of auto-sympathectomy leading
to peripheral vasodilatation in diabetic patients with
neuropathy is a well described phenomenon.12 Edmonds et
al13 further suggest that significant arteriovenous shunting
takes place in the feet of neuropathic diabetic patients leading
to abnormal bone cell activity and eventual resorption and
weakening of the bone.
Autonomic neuropathy leads to increased blood flow with
osteopenia thus weakening the bone and making it more
susceptible to injury.14 However, Charcot foot may also occur
following major trauma, such as fractured ankle and has been
reported during bed rest.15 An adequate blood supply appears
to be crucial as Charcot foot is not seen in ischaemic feet,
but has been reported following successful
revascularization.11
Diabetic sensory neuropathy
↓
Loss of protective sensation
↓
Repeated microtrauma
↓
Increased local blood flow
↓
Bone resorption
↓
Microfractures
↓
Acute Charcot foot
Figure 1.  Schematic diagram showing development of Charcot foot.
Fig 2a.  Clinical appearance of Charcot’s foot.
Fig 2b.  Radiological appearance of same patient.
ACUTE CHARCOT FOOT
The patient with an acute Charcot foot
usually presents with a hot, swollen,
erythematosus foot which may be several
degrees warmer than the contralateral foot and
crepitus may be noted on manipulation of the
foot.  Typically, the patient may recall some
minor trauma, perhaps weeks before.
Sometimes there may be concomitant
ulceration in the foot.  Although the Charcot
foot is often described as painless, patients will
usually have some pain and discomfort.
However, the level of pain reported by patients
is normally considerably less than might be
expected from the pathology seen.
Deformity may be evident at presentation.
Depending on the timing of presentation, X
rays may show no changes or healing fractures of the
meta-tarsals or subluxation and dislocation of one or
more joints.  The most commonly affected site is the
mid-foot (60% of patients) followed by the meta
tarsophalangeal joints (30%) and the ankle joint
(10%).  Because of its mode of presentation, the acute
charcot foot may be mistaken for infection with
cellulitis and osteomyelitis.  A useful clinical test is
to adequately elevate the foot for five minutes.  The
erythema of a Charcot foot will recede, whereas that
of a cellulitis foot will not.16
The results of nuclear medicine and magnetic
resonance imaging scans must also be interpreted with
caution as it is not easy to differentiate the acute
Charcot foot from infection with osteomyelitis.16  That
can lead to inappropriate surgery to deal with non-
existent infection.
STAGES OF THE CHARCOT FOOT
fragmentation and joint subluxation, dislocation and
destruction.  During this stage, the longitudinal arch of the
foot may collapse, giving rise to a rocker bottom foot or mid
The Charcot foot develops through three stages.17
Stage I : The Stage of Development, there is acute
inflammation with hyperaemia, bone softening and
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foot subluxation in the transverse plane which causes this
typical deformity.  Subluxation at the ankle joint may lead
to marked varus and valgus deformity such that the patient
is no longer walking on a plantigrade foot.
Stage II : The Stage of Coalescence, periosteal new bone
formation is apparent along with reduction of swelling.
Stage III :  The stage of Reconstruction, bony
consolidiation takes place and healing occurs.
Stage I represents the acute Charcot foot and Stages II
and II, the reparative process.  Progress through all the three
stages, may take up to 2-3 years, although the acute phase
may settle over a period of months.
RADIOLOGICAL CLASSIFICATION OF
CHARCOT FOOT
Radiologically, Charcot’s foot has been categorized as
atrophic and proliferative types.
Atrophic Type :  This type of disease is not commonly
seen in the fore-foot.  Marked osseous resorption of bone
results in ‘pencil pointing’ or ‘sucked candy’ deformities of
the metatarsal heads and shafts.  These changes may be totally
asymptomatic or may cause minimal signs and thus are only
discovered accidentally on X-ray films.
Proliferative Type :  This is the more common type and
hence is more significant clinically.  Proliferative or
hypertrophic Charcot’s disease affects the larger joints of
the foot (i.e., mid-foot and rear foot) and there is destruction
of bone followed by new bone formation.
INVESTIGATIONS IN CHARCOT FOOT
The diagnosis of Charcot foot remains primarily clinical,
particularly in the early stages and the purpose of
investigations is to distinguish charcot foot from other
conditions that cause pain and swelling of the foot such as
osteomyelitis, inflammatory arthritis, cellulitis, trauma, deep
vein thrombosis or gout.18
The investigations required for diagnosis of Charcot foot
has been recently reviewed by Rajbhandari et al.19  The
review suggests that even when the diagnosis is considered
at an early stage, there are no definitive criteria or tests to
confirm Charcot’s neuroarthropathy and a high index of
suspicion is necessary in any diabetic patient with a swollen
warm foot in the presence of somatic or autonomic
neuropathy.19
Plain X ray :  The X ray of forefoot can show
demineralization, bone destruction and periosteal reaction.
Severe changes can develop in this form of Charcot foot with
pencil and cup deformity at the metatarsophalangeal joints
or fragmentation of the metatarsal heads.20  In the midfoot,
dislocation or fracture develops after initial joint swelling
and ligamentous laxity.
Radionuclide (Isotope) Imaging :  Radionuclide imaging
can be a useful investigative tool in some instances.  The
three phase bone scan using technetium (TC-MDP) will be
positive in all three phases and merely reflects the increased
turnover of bone in Charcot foot.  It is very sensitive but not
very specific.  Labeled white cell scans (In-WBC) show
increased activity at the site of infection but do not pick up
new bone formation.  Therefore, a combination of three phase
TCMDP and In-WBC scans, which has a sensitivity and
specificity of 80% to 90% is valuable for diagnosis if there
is a penetrating ulcer underneath the deformity.21
Computerized Tomography (CT) and Magnetic
Resonance (MR) Imaging : Computerized tomography
scanning can detect the presence of sequestra, cortical
destruction, periosteal reaction and intraosseous gas which
might not be detected on MR imaging.  However, magnetic
resonance is superior for soft tissue imaging, gives exquisite
anatomical detail22-25 and has largely superceded CT.
Magnetic resonance scan of foot is extremely sensitive26
having a 100% detection of abnormalities and thus the most
sensitive modality discussed so far.
TREATMENT
Conservation Line of Management
The mainstay of therapy for acute Charcot’s disease of
the midfoot and rearfoot is immobilization, i.e., total
prohibition from placing weight on the affected foot.
Treatment of Charcot foot is aimed at reducing the swelling,
minimising residual deformity and thus reducing the risk of
neuropathic foot ulceration.  Some centres will aim to reduce
the swelling and mechanical stress by means of bed rest,
elevation and non-weight bearing with crutches or a
wheelchair.  The disadvantage of this is that the acute phase
may last for six months or so and patients with neuropathy
and loss of sensation may not be compliant with this.
Prolonged non-weight bearing may increase osteoporosis and
further weaken the bone.
Use of either the total contact case,27 which is an excellent
means of reducing swelling or the diabetic aircast walker
with inflatable air cells, which some patients can tolerate
better over a prolonged period of time.  A total contact insole
can be made for the walker.  The aim of the total contact cast
is to both reduce swelling and try to hold the shape of the
foot while the bone is soft and deformable.
In recent years there has also been interest in the use of
drugs designed to reduce bone turnover, by inhibiting
osteoclastic activity as means of helping to settle the acute
Charcot foot.28  It is shown that intravenous bisphosphonate
rapidly reverses the paradoxical increase in blood flow by
antagonizing inflammatory mediators that increase blood
flow and bone resorption in Charcot neuroarthropathy.
Bisphosphonates have also been reported to improve pain
and heat in the Charcot foot.29
Surgical Management
In the acute stage I of the Charcot foot, surgery is almost
totally contraindicated.30  Metal work will not hold in soft
fragmenting bone and the literature refers to many poor
results from attempted arthrodesis.5  The exception to this
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may be the acute unstable but manually reducible dislocation.
Under this circumstances, success has been reported in
obtaining stable reduction.31  However, any bony
fragmentation or periosteal new bone formation is a
contraindication.
Once the Charcot foot has reached a quiescent stage the
patient is usually left with a neuropathic, deformed foot which
is liable to recurrent ulceration over the bony prominences.
Again, initial treatment will tend to be orthotic with footwear
and insoles.  However, recurrent ulceration in the presence
of a fixed deformity will be an indication for surgery.  Under
these circumstances, surgery is indicated either to remove
the bony prominences or correct deformities to produce a
plantigrade foot which can be managed with orthotics.  A
further indication for surgery may be deep infection with
abscess formation or osteomyelitis which may necessitate
drainage or removal of infected bone.  In one series, 50% of
patients required surgery, including 21 major limb
amputations.32
Exostectomy
Removal of bony prominences is perhaps most common
the ‘Rocker Bottom Foot’, where patients develops a plantar
mid-foot prominence which is liable to recurrent breakdown.
Before any surgery, it may be preferable to heal the
ulceration, if practical, in order to minimize infection risk.
It is also important to establish that there is no underlying
osteomyelitis within the bony prominence.
Diagnosing osteomyelitis in the Charcot foot is not straight
forward because of the already abnormal bony architecture.
It may be necessary to do a bone scan in conjunction with an
indium white cell labeled scan.  If osteomyelitis is present,
then a wider excision of bone may be indicated.
A midfoot plantar exostosis can be excised through an
incision along the medial or lateral border of the foot.  The
soft tissues are stripped off the underlying bone and then
either an oscillating saw or osteotome is used to remove the
prominence and flatten the bony surface.  The greater the
surface area supporting weight, the less there will be of point
loading with high peak pressures.  A drain is normally used
to reduce postoperative haematoma.  Postoperatively, the
wound is allowed to settle and weight bearing can then be
commenced with or without a cast depending on whether
any ulceration is still present.
Arthrodesis
Arthrodesis is usually reserved for midfoot and hindfoot
deformities that are unbraceable and causing recurrent
ulceration.  This is a considerably more complex surgery
that carries the risk of amputation if it is unsuccessful.  In
many cases however it can avoid the need for amputation
and the significantly higher energy requirements of walking
with an artificial leg.  Once a person with diabetes has had
one leg amputated, there is a high incidence of contralateral
amputation within a few years.33
CLASSIFICATION OF DEFORMITIES
A number of different classifications have been proposed
for the different patterns of involvement in Charcot foot.
Brodsky et al34 suggested an anatomical classification into
three main groups as follows:
1. Type 1 involving the tarsometatarsal and
naviculocuneiform joints
2 Type 2 involving the subtalar complex including the
talonavicular and calcaneocuboid joints.
3. Type 3A involving the tibiotalar joint and Type 3 B
involving the posterior process of the calcaneum, which
may develop a neuropathic fracture.
In Type 1 and 2, arthrodesis, rather than exostectomy,
may be indicated where midfoot deformities are unstable
and the Achilles tendon is tight, which exacerbates the rocker
deformity.  Realignment involves open reduction of the
deformity and often, extensive fixation with interfragmentary
screws.  If the bone is too soft for solid fixation with screws,
the fragments may be held with pins.  Lengthening of the
Achilles tendon may also be necessary.
Type 3 ankle involvement may cause marked
malalignment in the coronal plane.  Arthrodesis of the of the
ankle joint can be accomplished in a standard manner with
screw fixation if the hold on the bone is sufficiently good.  If
the bone is soft or a tibiocalcaneal arthrodesis is necessary,
then an external fixator, such as the calandruccio clamp can
be used or an intramedullary nail driven up through the heel.
If an intramedullary nail is used then both the ankle and
subtalar joints will be fixed.
Post-operative management may involve lengthy periods
in plaster while bony union is taking place.  Although some
series have achieved good rates of union, solid bony union
does not always occur.  A number of these patients will
stabilize through with a fibrous ankylosis and the deformity
will be corrected sufficiently to adequately brace the foot
and avoid recurrent ulceration.  Nevertheless, this is not easy
surgery and most series have significant complication rates.
Twenty complications in 19 patients were reported in a series
of 29 patients with neuro arthropathy.35  Ten of the 29 patients
had a pseudoarthrosis although seven of these were stable.
One patient required a below knee amputation.  However,
all of these deformities were severe and amputation would
have been an alternative to arthrodesis.
COMPLICATIONS
Almost all complications related to Charcot’s foot are the
result of distortion of the normal bony architecture of the
foot.  The most common deformity resulting from Charcot’s
disease of the mid foot is the Rocker Bottom Foot, caused
by overloading of the medial aspect of plantar prominent
bones.  A less common but far more troublesome
complication is Inversion Deformity resulting from excessive
weight and pressure at the base of the fifth metatarsal and
cuboid bones.  This deformity is very difficult to control
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with conservative means alone.  Late diagnosis or patient
non-compliance may result in significant bony deformities.
Severe deformities causing bony prominences may result in
areas of excessive pressure and chronic ulceration.  Besides
limiting the patient’s activity, these ulcerations may result
in infection and possibly osteomyelitis.
Although some residual deformity (chronic swelling) will
always remain in patients who have had severe Charcot’s
disease, significant and troublesome skeletal deformities can
be avoided with prompt treatment.
SPECIAL FOOTWEAR
An active Charcot foot should be immobilized in a plaster
cast until the condition has stabilized (cooled-off) and the
required footwear is ready.36  A cooled-off Charcot foot
requires a shoe that prevents further collapse of the foot which
is similar to a plaster case.37,38  In other words, it requires a
high, stiffened shoe that has a full contact insole and a rocker
bottom sole with an early pivot point and shock absorption
through the heel.
CONCLUSIONS
Although Charcot’s disease and its association with
diabetes have been described many times in the literature, it
is still often misdiagnosed and incorrectly treated as
osteomyelitis, arthritis or gout.  The best safeguard is a high
index of suspicion.  A warm swollen foot in a diabetic patient
with long standing neuropathy without local or systemic signs
of infection must be considered Charcot’s foot until proven
otherwise.  The principle treatment is total abstinence from
putting weight on the foot until warmth, swelling and redness
subside.  Protective weight bearing methods may then be
slowly instituted.
The Charcot foot represents a formidable clinical
challenge.  There is much that is still not understood about
it, but indications for surgery and techniques of stabilizing
the foot have advanced considerably over the last decade.
Perhaps, better control of diabetes and improved treatment
of neuropathy may help to prevent this potentially crippling
disorder.
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